Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / France

European Innovation Council · Ended early

DOWN-AUTONOMY LCTB-21: A DYRK1A protein kinase inhibitor for treatment of cognitive decline in Down Syndrome.

Coordinator
Perha Pharmaceuticals SAS, France
Runs
1 June 2022 to 30 June 2026
Status
Ended early
EU funding
€2.5m
Total cost
€11.4m
Partners
1 organisations in 1 countries
Type
European Innovation Council
Grant agreement
190138295

What the project is doing

In the project's own words, from its summary on CORDIS.

All people with Down Syndrome (DS) suffer from a certain level of impaired learning and memory (cognitive disorders) from childhood onwards, greatly impacting their autonomy and societal integration. This is becoming an increasingly urgent issue as people with DS are more often outliving their care takers, yet an adequate treatment has not yet been developed. Studies have revealed that the cognitive decline in people with DS is associated with overexpression of the DYRK1A protein kinase in the brain.

Perha Pharmaceuticals has developed a novel therapeutic compound, Leucettinib-21 (LCTB-21), which acts as a DYRK1A inhibitor that can reduce cognitive decline in children with DS. Ultimately, this will increase the autonomy of people with DS resulting in better societal integration. Perha Pharmaceuticals aims to outlicense LCTB-21 to a large pharmaceutical partner (e.g. Otsuka Pharmaceuticals, Intra-Cellular Therapies) following a successful phase 2a clinical trial.

Topics

Who is involved

OrganisationCityCountryRole
Perha Pharmaceuticals SASRoscoffFranceCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI